Mary Ann Melnick

2.1k total citations · 1 hit paper
14 papers, 977 citations indexed

About

Mary Ann Melnick is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mary Ann Melnick has authored 14 papers receiving a total of 977 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Mary Ann Melnick's work include Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). Mary Ann Melnick is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (3 papers). Mary Ann Melnick collaborates with scholars based in United States, Japan and Netherlands. Mary Ann Melnick's co-authors include Katerina Politi, Marc Ladanyi, Valentina Pirazzoli, Yelena Y. Janjigian, Vincent A. Miller, Ken Takezawa, Elisa de Stanchina, Caroline A. Nebhan, Paula J. Spitzler and Mark G. Kris and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Mary Ann Melnick

14 papers receiving 970 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

2012 555 citations Ken Takezawa, Valentina Pirazzoli et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Ann Melnick United States	9	676	586	491	261	89	14	977
Junpei Takashima Japan	4	718 1.1×	604 1.0×	483 1.0×	210 0.8×	104 1.2×	17	946
Jih‐Hsiang Lee Taiwan	19	561 0.8×	669 1.1×	347 0.7×	196 0.8×	59 0.7×	37	1.0k
G. Jeannin France	9	543 0.8×	465 0.8×	408 0.8×	165 0.6×	105 1.2×	21	840
J. A. Engelman United States	12	1.0k 1.5×	834 1.4×	511 1.0×	257 1.0×	119 1.3×	24	1.3k
Shinnosuke Ikemura Japan	18	487 0.7×	485 0.8×	494 1.0×	233 0.9×	66 0.7×	46	959
Toshiki Takemoto Japan	15	616 0.9×	527 0.9×	381 0.8×	161 0.6×	83 0.9×	40	957
Tatsushi Kodama Japan	6	806 1.2×	761 1.3×	525 1.1×	118 0.5×	103 1.2×	8	1.1k
Johannes M. Heuckmann Germany	14	740 1.1×	685 1.2×	769 1.6×	232 0.9×	114 1.3×	21	1.3k
Ken Uchibori Japan	15	614 0.9×	567 1.0×	360 0.7×	156 0.6×	64 0.7×	59	885

Countries citing papers authored by Mary Ann Melnick

Since Specialization

Citations

This map shows the geographic impact of Mary Ann Melnick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Ann Melnick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Ann Melnick more than expected).

Fields of papers citing papers by Mary Ann Melnick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Ann Melnick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Ann Melnick. The network helps show where Mary Ann Melnick may publish in the future.

Co-authorship network of co-authors of Mary Ann Melnick

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Ann Melnick. A scholar is included among the top collaborators of Mary Ann Melnick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Ann Melnick. Mary Ann Melnick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Hu, Bomiao, Fernando J. de Miguel, Zongzhi Liu, et al.. (2024). ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts. Cancer Research. 84(8). 1303–1319. 18 indexed citations

Mack, Philip C., Jieling Miao, Mary W. Redman, et al.. (2022). Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403). Clinical Cancer Research. 28(17). 3752–3760. 31 indexed citations

Goldberg, Sarah B., Mary W. Redman, Rogério Lilenbaum, et al.. (2020). Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403. Journal of Clinical Oncology. 38(34). 4076–4085. 52 indexed citations

Mack, Philip C., Mary W. Redman, James Moon, et al.. (2020). Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.. Journal of Clinical Oncology. 38(15_suppl). 9532–9532. 6 indexed citations

Zhang, Wen Cai, Julie Wells, Kin-Hoe Chow, et al.. (2019). miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. Nature Metabolism. 1(4). 460–474. 57 indexed citations

Bryant, Kelly G., Jae Ho Seo, Qin Liu, et al.. (2019). Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor. American Journal Of Pathology. 189(6). 1180–1189. 4 indexed citations

Goldberg, Sarah B., Mary W. Redman, Rogério Lilenbaum, et al.. (2018). OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403. Journal of Thoracic Oncology. 13(10). S343–S344. 5 indexed citations

Goldberg, Sarah B., James Moon, Rogério Lilenbaum, et al.. (2017). P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403. Journal of Thoracic Oncology. 12(1). S1220–S1221. 1 indexed citations

Suda, Kenichi, Leslie Rozeboom, Koh Furugaki, et al.. (2017). Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. BioMed Research International. 2017. 1–7. 12 indexed citations

10.

Suda, Kenichi, Leslie Rozeboom, Christopher J. Rivard, et al.. (2017). MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer. Journal of Thoracic Oncology. 12(1). S433–S434. 1 indexed citations

11.

Suda, Kenichi, Leslie Rozeboom, Christopher J. Rivard, et al.. (2017). Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer. 109. 1–8. 26 indexed citations

12.

Forloni, Matteo, Romi Gupta, Arvindhan Nagarajan, et al.. (2016). Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. Cell Reports. 16(2). 457–471. 55 indexed citations

13.

Bruin, Elza C. de, Catherine Cowell, Patricia H. Warne, et al.. (2014). Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer Discovery. 4(5). 606–619. 154 indexed citations

14.

Takezawa, Ken, Valentina Pirazzoli, Maria E. Arcila, et al.. (2012). HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation. Cancer Discovery. 2(10). 922–933. 555 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact